Denson D D, Myers J A, Coyle D E
Res Commun Chem Pathol Pharmacol. 1984 Sep;45(3):323-30.
The effect of meperidine at two clinically relevant concentrations (0.4 and 0.8 microgram/ml) on the serum protein binding of bupivacaine was studied. The serum protein binding profile for meperidine was characterized over a wide concentration range (0.5-100 micrograms/ml). All bupivacaine binding experiments were characterized by a two classes of binding sites model. Bupivacaine binding was independent of added meperidine. Meperidine binding was characterized by a one class of binding sites model and the unbound meperidine concentration was relatively constant over the entire range studied. The capacity and affinity of the meperidine binding site are suggestive of binding primarily to albumin. At clinically encountered meperidine concentrations, no increased toxicity due to an increase in unbound bupivacaine would be expected.
研究了哌替啶在两个临床相关浓度(0.4和0.8微克/毫升)下对布比卡因血清蛋白结合的影响。在较宽的浓度范围(0.5 - 100微克/毫升)内对哌替啶的血清蛋白结合情况进行了表征。所有布比卡因结合实验均采用两类结合位点模型进行表征。布比卡因的结合与添加的哌替啶无关。哌替啶的结合采用一类结合位点模型进行表征,并且在整个研究范围内未结合的哌替啶浓度相对恒定。哌替啶结合位点的容量和亲和力表明其主要与白蛋白结合。在临床遇到的哌替啶浓度下,预计不会因未结合布比卡因的增加而导致毒性增加。